1
|
Aschero R, Ganiewich D, Lamas G, Restrepo-Perdomo CA, Ottaviani D, Zugbi S, Camarero S, Néspoli E, Vilanova MC, Perez-Jaume S, Pascual-Pasto G, Sampor C, Grigorovski N, Salas B, Suñol M, Carcaboso AM, Mora J, de Dávila MTG, Doz F, Radvanyi F, Abramson DH, Llera AS, Schaiquevich PS, Lubieniecki F, Chantada GL. Immunohistochemical expression of TFF1 is a marker of poor prognosis in retinoblastoma. Pediatr Blood Cancer 2024; 71:e30717. [PMID: 37814421 DOI: 10.1002/pbc.30717] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/28/2023] [Revised: 09/27/2023] [Accepted: 09/28/2023] [Indexed: 10/11/2023]
Abstract
INTRODUCTION The risk of relapse in retinoblastoma is currently determined by the presence of high-risk histopathologic factors in the enucleated eye. However, the probability of developing metastatic disease is heterogeneous among these patients. Evaluating a biological marker to identify high-risk patients could be useful in clinical setting. This study aims to evaluate whether the expression of TFF1, a surrogate for subtype 2 retinoblastoma, is a prognostic marker for relapse and death. METHODS This multicenter cohort study included 273 patients, 48 of whom had extraocular disease. Immunohistochemical staining were performed for CRX, ARR3, TFF1, and Ki67. Tumors were classified as histological subtype 1 (HS1) if they had low or no expression of TFF1 (quick score (QS) ≤ 50) and as histological subtype 2 (HS2) if they expressed TFF1 diffusely (QS > 50). We studied the association between HS classification and outcome. RESULTS Of 273 patients, 35.9% were classified as HS1, 59.3% as HS2 and 4.8% were not evaluable. In multivariate analysis, patients with HS2 tumors had a higher probability of relapse and death than those with HS1 (p < .0001 and p = .00020, respectively). We identified a higher-risk subgroup among HS2 tumors, presenting non-mutually exclusive expression of ARR3 and TFF1 and had an increased risk of relapse and death compared with tumors that displayed mutually exclusive expression (p = .012 and p = .027, respectively). CONCLUSIONS Expression of TFF1, especially when it is not-mutually exclusive with ARR3, is an independent significant marker of poor outcome in retinoblastoma.
Collapse
Affiliation(s)
- Rosario Aschero
- Pathology Service, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina
- National Scientific and Technical Research Council, CONICET, Buenos Aires, Argentina
- SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Barcelona, Spain
- Institut de Recerca Sant Joan de Deu, Barcelona, Spain
| | - Daiana Ganiewich
- Instituto de Investigaciones en Medicina Traslacional - Universidad Austral, Buenos Aires, Argentina
| | - Gabriela Lamas
- Pathology Service, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina
| | | | - Daniela Ottaviani
- SIREDO Center, Institut Curie and University Paris Cité, Paris, France
| | - Santiago Zugbi
- National Scientific and Technical Research Council, CONICET, Buenos Aires, Argentina
- Unidad de tratamientos innovadores, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina
| | - Sandra Camarero
- Pathology Service, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina
| | - Ezequiel Néspoli
- Pathology Service, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina
| | - Maria Cuadrado Vilanova
- SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Barcelona, Spain
- Institut de Recerca Sant Joan de Deu, Barcelona, Spain
| | - Sara Perez-Jaume
- SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Barcelona, Spain
- Institut de Recerca Sant Joan de Deu, Barcelona, Spain
| | - Guillem Pascual-Pasto
- SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Barcelona, Spain
- Institut de Recerca Sant Joan de Deu, Barcelona, Spain
| | - Claudia Sampor
- Hematology-Oncology Service, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina
| | - Nathalia Grigorovski
- Department of Pediatric Oncology, Clinical Division, National Institute of Cancer, Rio de Janeiro, Brazil
| | - Beatriz Salas
- Department of Pediatric Oncology, Hospital del Niño Manuel A. Villarroel, Cochabamba, Bolivia
| | - Mariona Suñol
- Pathology Service, Hospital Sant Joan de Deu, Barcelona, Spain
| | - Angel M Carcaboso
- SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Barcelona, Spain
- Institut de Recerca Sant Joan de Deu, Barcelona, Spain
| | - Jaume Mora
- SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Barcelona, Spain
- Institut de Recerca Sant Joan de Deu, Barcelona, Spain
| | - María T G de Dávila
- Pathology Service, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina
| | - François Doz
- SIREDO Center, Institut Curie and University Paris Cité, Paris, France
| | - François Radvanyi
- SIREDO Center, Institut Curie and University Paris Cité, Paris, France
| | - David H Abramson
- Ophthalmic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
| | - Andrea S Llera
- National Scientific and Technical Research Council, CONICET, Buenos Aires, Argentina
- Instituto de Investigaciones en Medicina Traslacional - Universidad Austral, Buenos Aires, Argentina
- Laboratory of Molecular and Cellular Therapy, Instituto Leloir-Instituto de Investigaciones Bioquímicas de Buenos Aires (IIBBA), Buenos Aires, Argentina
| | - Paula S Schaiquevich
- National Scientific and Technical Research Council, CONICET, Buenos Aires, Argentina
- Unidad de tratamientos innovadores, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina
| | - Fabiana Lubieniecki
- Pathology Service, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina
| | - Guillermo L Chantada
- National Scientific and Technical Research Council, CONICET, Buenos Aires, Argentina
- SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Barcelona, Spain
- Institut de Recerca Sant Joan de Deu, Barcelona, Spain
- Hematology Oncology Service, Hospital Pereyra Rossell, Montevideo, Uruguay
| |
Collapse
|
2
|
Zugbi S, Aschero R, Ganiewich D, Cancela MB, Winter U, Ottaviani D, Sampor C, Dinardi M, Torbidoni AV, Mena M, Balaguer-Lluna L, Lamas G, Sgroi M, Lagomarsino E, Lubieniecki F, Fandiño A, Radvanyi F, Abramson DH, Podhajcer O, Llera AS, Cafferata EG, Chantada G, Carcaboso AM, Schaiquevich P. Establishment and Comprehensive Characterization of a Novel Preclinical Platform of Metastatic Retinoblastoma for Therapeutic Developments. Invest Ophthalmol Vis Sci 2023; 64:27. [PMID: 38117242 PMCID: PMC10741097 DOI: 10.1167/iovs.64.15.27] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2023] [Accepted: 11/20/2023] [Indexed: 12/21/2023] Open
Abstract
Purpose Although there have been improvements in the management of metastatic retinoblastoma, most patients do not survive, and all patients suffer from multiple short- and long-term treatment toxicities. Reliable and informative models to assist clinicians are needed. Thus we developed and comprehensively characterized a novel preclinical platform of primary cell cultures and xenograft models of metastatic retinoblastoma to provide insights into the molecular biology underlying metastases and to perform drug screening for the identification of hit candidates with the highest potential for clinical translation. Methods Orbital tumor, bone marrow, cerebrospinal fluid, and lymph node tumor infiltration specimens were obtained from seven patients with metastatic retinoblastoma at diagnosis, disease progression, or relapse. Tumor specimens were engrafted in immunodeficient animals, and primary cell lines were established. Genomic, immunohistochemical/immunocytochemical, and pharmacological analysis were performed. Results We successfully established five primary cell lines: two derived from leptomeningeal, two from orbital, and one from lymph node tumor dissemination. After the intravitreal or intraventricular inoculation of these cells, we established cell-derived xenograft models. Both primary cell lines and xenografts accurately retained the histological and genomic features of the tumors from which they were derived and faithfully recapitulated the dissemination patterns and pharmacological sensitivity observed in the matched patients. Conclusions Ours is an innovative and thoroughly characterized preclinical platform of metastatic retinoblastoma developed for the understanding of tumor biology of this highly aggressive tumor and has the potential to identify drug candidates to treat patients who currently lack effective treatment options.
Collapse
Affiliation(s)
- Santiago Zugbi
- Innovative Treatments Unit, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina
- National Scientific and Technical Research Council, CONICET, Buenos Aires, Argentina
| | - Rosario Aschero
- National Scientific and Technical Research Council, CONICET, Buenos Aires, Argentina
- Pathology Service, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina
- SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Institut de Recerca Sant Joan de Deu, Barcelona, Spain
| | - Daiana Ganiewich
- Laboratory of Molecular and Cellular Therapy, Instituto Leloir – Instituto de Investigaciones Bioquímicas de Buenos Aires (IIBBA), Buenos Aires, Argentina
| | - María B. Cancela
- Innovative Treatments Unit, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina
- National Scientific and Technical Research Council, CONICET, Buenos Aires, Argentina
| | - Ursula Winter
- Innovative Treatments Unit, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina
- Pathology Service, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina
| | - Daniela Ottaviani
- Institut Curie; PSL Research University, Centre National de la Recherche Scientifique (CNRS); Equipe Ligue contre le cancer, Paris, France
| | - Claudia Sampor
- Hematology-Oncology Service, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina
| | - Milagros Dinardi
- Innovative Treatments Unit, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina
| | - Ana V. Torbidoni
- Innovative Treatments Unit, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina
- National Scientific and Technical Research Council, CONICET, Buenos Aires, Argentina
| | - Marcela Mena
- Laboratory of Molecular and Cellular Therapy, Instituto Leloir – Instituto de Investigaciones Bioquímicas de Buenos Aires (IIBBA), Buenos Aires, Argentina
| | - Leire Balaguer-Lluna
- SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Institut de Recerca Sant Joan de Deu, Barcelona, Spain
| | - Gabriela Lamas
- Pathology Service, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina
| | - Mariana Sgroi
- Ophthalmology Service, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina
| | - Eduardo Lagomarsino
- Pharmacy Service, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina
| | - Fabiana Lubieniecki
- Pathology Service, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina
| | - Adriana Fandiño
- Ophthalmology Service, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina
| | - François Radvanyi
- Institut Curie; PSL Research University, Centre National de la Recherche Scientifique (CNRS); Equipe Ligue contre le cancer, Paris, France
| | - David H. Abramson
- Ophthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, United States
| | - Osvaldo Podhajcer
- National Scientific and Technical Research Council, CONICET, Buenos Aires, Argentina
- Laboratory of Molecular and Cellular Therapy, Instituto Leloir – Instituto de Investigaciones Bioquímicas de Buenos Aires (IIBBA), Buenos Aires, Argentina
| | - Andrea S. Llera
- National Scientific and Technical Research Council, CONICET, Buenos Aires, Argentina
- Laboratory of Molecular and Cellular Therapy, Instituto Leloir – Instituto de Investigaciones Bioquímicas de Buenos Aires (IIBBA), Buenos Aires, Argentina
| | - Eduardo G. Cafferata
- National Scientific and Technical Research Council, CONICET, Buenos Aires, Argentina
- Laboratory of Molecular and Cellular Therapy, Instituto Leloir – Instituto de Investigaciones Bioquímicas de Buenos Aires (IIBBA), Buenos Aires, Argentina
| | - Guillermo Chantada
- National Scientific and Technical Research Council, CONICET, Buenos Aires, Argentina
- SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Institut de Recerca Sant Joan de Deu, Barcelona, Spain
| | - Angel M. Carcaboso
- SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Institut de Recerca Sant Joan de Deu, Barcelona, Spain
| | - Paula Schaiquevich
- Innovative Treatments Unit, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina
- National Scientific and Technical Research Council, CONICET, Buenos Aires, Argentina
| |
Collapse
|
3
|
Ganiewich D, Zugbi S, Aschero R, Ottaviani D, Cancela MB, Lubieniecki F, Sampor C, Lavarino C, Radvanyi F, Chantada GL, Schaiquevich PS, Llera AS. Abstract 2500: Metastatic retinoblastoma exhibit MYCN alterations, recurrent CNAs and hypomethylation as molecular characteristics of aggressive disease. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-2500] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Retinoblastoma is a rare pediatric malignancy but the most frequent tumor of the eye. Metastatic disease is the most common cause of disease-related death and is rare in high-income countries. Therefore, little is known about the genomics, transcriptomics and methylomics of extraocular retinoblastoma. Here we present a series of extraocular retinoblastoma cases analyzed at DNA, RNA and methylation level to elucidate the landscape of the metastatic disease. These samples were analyzed by OncoScan CNV, CytoScan HD or whole-exome sequencing, depending on sample availability, for CNA (clonal and subclonal) and mutation analysis; RNAseq for fusion and expression data, and Infinium MethylationEPIC assay for methylation examination. Hierarchical clustering and subtype classification was performed using previously published expression and methylation signatures. Cell cultures were successfully established for 4 tumor specimens. In vitro pharmacological sensitivity of those cell cultures was determined by MTT assay. In total, 11 patients and 14 samples were studied (55% male, 64% unilateral). One patient was RB+/+ and harbored a MYCN amplification. Dissemination sites included orbit (n=8), systemic (n=3), and central nervous system (n=5). Median age at diagnosis was 27 months (5-48); 36% were already metastatic. All samples were classified as subtype 2 retinoblastoma according to Liu et. al., 2021, both at the expression and methylation level. Among recurrent CNAs in all samples, common retinoblastoma alterations were observed: 1q (86%), 2p (71%, 29% MYCN amplified), 6p (93%) gains and 16q (64%) loss. Other less frequent alterations such as 17q gain (21%) and 11q (43%) and 19q (29%) loss were found. MYCN pathway alteration was the most outstanding feature, evidenced by frequent gains/amplification on that gene and in gene-expression clustering based on MYCN expression signatures. Global hypomethylation was also observed when comparing metastatic to intraocular samples and it was consistent with the general gene overexpression seen in metastatic samples. Metastasis-derived in vitro cultures treated either with melphalan, topotecan, idarubicin, doxorubicin or carboplatin showed various degrees of sensitivity (i.e. EC50 in the nM to mM range), with no clear association to MYCN overexpression. In conclusion, even considering the caveats regarding our current sample size, we could detect the alteration of the MYCN pathway as a distinct characteristic of extraocular retinoblastoma. Global hypomethylation has been related to the activation of oncogenic drivers and is consistent with metastatic behavior. These results suggest a pattern of molecular features that may have been selected during tumor evolution. Our results do not support a straightforward relationship between MYCN activation and resistance to therapy.
Citation Format: Daiana Ganiewich, Santiago Zugbi, Rosario Aschero, Daniela Ottaviani, María B. Cancela, Fabiana Lubieniecki, Claudia Sampor, Cinzia Lavarino, François Radvanyi, Guillermo L. Chantada, Paula S. Schaiquevich, Andrea S. Llera. Metastatic retinoblastoma exhibit MYCN alterations, recurrent CNAs and hypomethylation as molecular characteristics of aggressive disease [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2500.
Collapse
Affiliation(s)
- Daiana Ganiewich
- 1Instituto Leloir-Instituto de Investigaciones Bioquímicas de Buenos Aires (IIBBA), Buenos Aires, Argentina
| | - Santiago Zugbi
- 2Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina
| | | | | | | | | | - Claudia Sampor
- 2Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina
| | | | | | - Guillermo L. Chantada
- 5Instituto de Investigaciones en Medicina Traslacional - Universidad Austral, Buenos Aires, Argentina
| | | | - Andrea S. Llera
- 1Instituto Leloir-Instituto de Investigaciones Bioquímicas de Buenos Aires (IIBBA), Buenos Aires, Argentina
| |
Collapse
|
4
|
Aschero R, Francis JH, Ganiewich D, Gomez-Gonzalez S, Sampor C, Zugbi S, Ottaviani D, Lemelle L, Mena M, Winter U, Correa Llano G, Lamas G, Lubieniecki F, Szijan I, Mora J, Podhajcer O, Doz F, Radvanyi F, Abramson DH, Llera AS, Schaiquevich PS, Lavarino C, Chantada GL. Recurrent Somatic Chromosomal Abnormalities in Relapsed Extraocular Retinoblastoma. Cancers (Basel) 2021; 13:cancers13040673. [PMID: 33567541 PMCID: PMC7915502 DOI: 10.3390/cancers13040673] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2021] [Revised: 01/26/2021] [Accepted: 02/01/2021] [Indexed: 02/07/2023] Open
Abstract
Simple Summary Relapse outside the eye of retinoblastoma (the most common eye cancer in children) is an uncommon event in developed countries, however it is the main cause of death in patients with retinoblastoma worldwide. The genomic features of this population are not known. We studied 23 cases from four countries and found a characteristic pattern in chromosomal copy number alterations that could help guide future clinical management of these patients. Abstract Most reports about copy number alterations (CNA) in retinoblastoma relate to patients with intraocular disease and features of children with extraocular relapse remain unknown, so we aimed to describe the CNA in this population. We evaluated 23 patients and 27 specimens from 4 centers. Seventeen cases had extraocular relapse after initial enucleation and six cases after an initial preservation attempt. We performed an analysis of CNA and BCOR gene alteration by SNP array (Single Nucleotide Polymorfism array), whole-exome sequencing, IMPACT panel and CGH array (Array-based comparative genomic hybridization). All cases presented CNA at a higher prevalence than those reported in previously published studies for intraocular cases. CNA previously reported for intraocular retinoblastoma were found at a high frequency in our cohort: gains in 1q (69.5%), 2p (60.9%) and 6p (86.9%), and 16q loss (78.2%). Other, previously less-recognized, CNA were found including loss of 11q (34.8%), gain of 17q (56.5%), loss of 19q (30.4%) and BCOR alterations were present in 72.7% of our cases. A high number of CNA including 11q deletions, 17q gains, 19q loss, and BCOR alterations, are more common in extraocular retinoblastoma. Identification of these features may be correlated with a more aggressive tumor warranting consideration for patient management.
Collapse
Affiliation(s)
- Rosario Aschero
- Pathology Service, Hospital de Pediatría JP Garrahan, Buenos Aires 1245, Argentina; (R.A.); (U.W.); (G.L.); (F.L.)
- National Scientific and Technical Research Council, CONICET, Buenos Aires 1425, Argentina; (S.Z.); (O.P.); (A.S.L.); (P.S.S.)
| | - Jasmine H. Francis
- Ophthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; (J.H.F.); (D.H.A.)
| | - Daiana Ganiewich
- Laboratory of Molecular and Cellular Therapy, Instituto Leloir-Instituto de Investigaciones Bioquímicas de Buenos Aires (IIBBA), Buenos Aires 1405, Argentina;
| | - Soledad Gomez-Gonzalez
- Developmental Tumor Biology Laboratory, Institut de Recerca Sant Joan de Déu, 08950 Barcelona, Spain; (S.G.-G.); (J.M.); (C.L.)
| | - Claudia Sampor
- Hematology-Oncology Service, Hospital de Pediatría JP Garrahan, Buenos Aires 1245, Argentina;
| | - Santiago Zugbi
- National Scientific and Technical Research Council, CONICET, Buenos Aires 1425, Argentina; (S.Z.); (O.P.); (A.S.L.); (P.S.S.)
- Innovative Treatments Unit, Hospital de Pediatría JP Garrahan, Buenos Aires 1245, Argentina;
| | - Daniela Ottaviani
- University of Paris and Institut Curie (SIREDO Center: Care, Innovation and Reserach in pediatric, Adolescent and Young Adults Oncology), CNRS, UMR144, Equipe Labellisée Ligue Contre le Cancer, 75005 Paris, France; (D.O.); (L.L.); (F.D.); (F.R.)
| | - Lauriane Lemelle
- University of Paris and Institut Curie (SIREDO Center: Care, Innovation and Reserach in pediatric, Adolescent and Young Adults Oncology), CNRS, UMR144, Equipe Labellisée Ligue Contre le Cancer, 75005 Paris, France; (D.O.); (L.L.); (F.D.); (F.R.)
| | - Marcela Mena
- Innovative Treatments Unit, Hospital de Pediatría JP Garrahan, Buenos Aires 1245, Argentina;
| | - Ursula Winter
- Pathology Service, Hospital de Pediatría JP Garrahan, Buenos Aires 1245, Argentina; (R.A.); (U.W.); (G.L.); (F.L.)
| | - Genoveva Correa Llano
- Pediatric Hematology and Oncology, Hospital Sant Joan de Déu, 08950 Barcelona, Spain;
| | - Gabriela Lamas
- Pathology Service, Hospital de Pediatría JP Garrahan, Buenos Aires 1245, Argentina; (R.A.); (U.W.); (G.L.); (F.L.)
| | - Fabiana Lubieniecki
- Pathology Service, Hospital de Pediatría JP Garrahan, Buenos Aires 1245, Argentina; (R.A.); (U.W.); (G.L.); (F.L.)
| | - Irene Szijan
- Genetic and Molecular Biology, University of Buenos Aires, Buenos Aires 1113, Argentina;
| | - Jaume Mora
- Developmental Tumor Biology Laboratory, Institut de Recerca Sant Joan de Déu, 08950 Barcelona, Spain; (S.G.-G.); (J.M.); (C.L.)
- Pediatric Hematology and Oncology, Hospital Sant Joan de Déu, 08950 Barcelona, Spain;
| | - Osvaldo Podhajcer
- National Scientific and Technical Research Council, CONICET, Buenos Aires 1425, Argentina; (S.Z.); (O.P.); (A.S.L.); (P.S.S.)
- Laboratory of Molecular and Cellular Therapy, Instituto Leloir-Instituto de Investigaciones Bioquímicas de Buenos Aires (IIBBA), Buenos Aires 1405, Argentina;
| | - François Doz
- University of Paris and Institut Curie (SIREDO Center: Care, Innovation and Reserach in pediatric, Adolescent and Young Adults Oncology), CNRS, UMR144, Equipe Labellisée Ligue Contre le Cancer, 75005 Paris, France; (D.O.); (L.L.); (F.D.); (F.R.)
| | - François Radvanyi
- University of Paris and Institut Curie (SIREDO Center: Care, Innovation and Reserach in pediatric, Adolescent and Young Adults Oncology), CNRS, UMR144, Equipe Labellisée Ligue Contre le Cancer, 75005 Paris, France; (D.O.); (L.L.); (F.D.); (F.R.)
| | - David H. Abramson
- Ophthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; (J.H.F.); (D.H.A.)
| | - Andrea S. Llera
- National Scientific and Technical Research Council, CONICET, Buenos Aires 1425, Argentina; (S.Z.); (O.P.); (A.S.L.); (P.S.S.)
- Laboratory of Molecular and Cellular Therapy, Instituto Leloir-Instituto de Investigaciones Bioquímicas de Buenos Aires (IIBBA), Buenos Aires 1405, Argentina;
| | - Paula S. Schaiquevich
- National Scientific and Technical Research Council, CONICET, Buenos Aires 1425, Argentina; (S.Z.); (O.P.); (A.S.L.); (P.S.S.)
- Innovative Treatments Unit, Hospital de Pediatría JP Garrahan, Buenos Aires 1245, Argentina;
| | - Cinzia Lavarino
- Developmental Tumor Biology Laboratory, Institut de Recerca Sant Joan de Déu, 08950 Barcelona, Spain; (S.G.-G.); (J.M.); (C.L.)
- Pediatric Hematology and Oncology, Hospital Sant Joan de Déu, 08950 Barcelona, Spain;
| | - Guillermo L. Chantada
- National Scientific and Technical Research Council, CONICET, Buenos Aires 1425, Argentina; (S.Z.); (O.P.); (A.S.L.); (P.S.S.)
- Pediatric Hematology and Oncology, Hospital Sant Joan de Déu, 08950 Barcelona, Spain;
- Correspondence:
| |
Collapse
|
5
|
Winter U, Ganiewich D, Ottaviani D, Zugbi S, Aschero R, Sendoya JM, Cafferata EG, Mena M, Sgroi M, Sampor C, Lubieniecki F, Fandiño A, Abba MC, Doz F, Podhjacer O, Carcaboso AM, Letouzé E, Radvanyi F, Chantada GL, Llera AS, Schaiquevich P. Genomic and Transcriptomic Tumor Heterogeneity in Bilateral Retinoblastoma. JAMA Ophthalmol 2021; 138:569-574. [PMID: 32191268 DOI: 10.1001/jamaophthalmol.2020.0427] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Importance Comprehensive understanding of the genomic and gene-expression differences between retinoblastoma tumors from patients with bilateral disease may help to characterize risk and optimize treatment according to individual tumor characteristics. Objective To compare the genomic features between each eye and a specimen from an orbital relapse in patients with bilateral retinoblastoma. Design, Setting, and Participants In this case, 2 patients with retinoblastoma underwent upfront bilateral enucleation. Tumor samples were subjected to genomic and gene-expression analysis. Primary cell cultures were established from both of the tumors of 1 patient and were used for gene-expression studies. Main Outcomes and Measures Whole-exome sequencing was performed on an Illumina platform for fresh tumor samples and DNA arrays (CytoScan or OncoScan) were used for paraffin-embedded samples and cell lines. Gene-expression analysis was performed using Agilent microarrays. Germinal and somatic alterations, copy number alterations, and differential gene expression were assessed. Results After initial bilateral enucleation, patient 1 showed massive choroidal and laminar optic nerve infiltration, while patient 2 showed choroidal and laminar optic nerve invasion. Patient 1 developed left-eye orbital recurrence and bone marrow metastasis less than 1 year after enucleation. Both ocular tumors showed gains on 1q and 6p but presented other distinct genomic alterations, including an additional gain in 2p harboring the N-myc proto-oncogene (MYCN) in the left tumor and orbital recurrence. Similar copy number alterations between the orbital recurrence and the left eye supported the origin of the relapse, with an additional 11q loss only detected in the orbital relapse. Specimens from patient 2 showed common copy number gains and losses, but further evolution rendered a 2p gain spanning MYCN in the left tumor. For this patient, microarray expression analysis showed differential expression of the MYCN and the forkhead box protein G1 (FOXG1) gene pathways between the left and right tumors. Conclusions and Relevance Differential genomic and gene expression features were observed between tumors in 2 patients with bilateral disease, confirming intereye heterogeneity that might be considered if targeted therapies are used in such patients. Chromosomal alteration profile supported the origin of the orbital recurrence from the homolateral eye in 1 patient. Loss in chromosome 11q may have been associated with extraocular relapse in this patient.
Collapse
Affiliation(s)
- Ursula Winter
- Precision Medicine, Hospital de Pediatría J.P. Garrahan, Buenos Aires, Argentina.,National Scientific and Technical Research Council, CONICET, Buenos Aires, Argentina
| | - Daiana Ganiewich
- Precision Medicine, Hospital de Pediatría J.P. Garrahan, Buenos Aires, Argentina.,Laboratory of Molecular and Cellular Therapy, Instituto Leloir, Buenos Aires, Argentina
| | - Daniela Ottaviani
- Centre National de la Recherche Scientifique, Unité Mixte de Recherche 144, Institut Curie, Paris, France
| | - Santiago Zugbi
- Precision Medicine, Hospital de Pediatría J.P. Garrahan, Buenos Aires, Argentina.,National Scientific and Technical Research Council, CONICET, Buenos Aires, Argentina
| | - Rosario Aschero
- National Scientific and Technical Research Council, CONICET, Buenos Aires, Argentina.,Pathology Service, Hospital de Pediatría J.P. Garrahan, Buenos Aires, Argentina
| | - Juan Martin Sendoya
- Laboratory of Molecular and Cellular Therapy, Instituto Leloir, Buenos Aires, Argentina
| | - Eduardo G Cafferata
- National Scientific and Technical Research Council, CONICET, Buenos Aires, Argentina.,Laboratory of Molecular and Cellular Therapy, Instituto Leloir, Buenos Aires, Argentina
| | - Marcela Mena
- Precision Medicine, Hospital de Pediatría J.P. Garrahan, Buenos Aires, Argentina
| | - Mariana Sgroi
- Ophthalmology Service, Hospital de Pediatría J.P. Garrahan, Buenos Aires, Argentina
| | - Claudia Sampor
- Oncology Service, Hospital de Pediatría J.P. Garrahan, Buenos Aires, Argentina
| | - Fabiana Lubieniecki
- Pathology Service, Hospital de Pediatría J.P. Garrahan, Buenos Aires, Argentina
| | - Adriana Fandiño
- Ophthalmology Service, Hospital de Pediatría J.P. Garrahan, Buenos Aires, Argentina
| | - Martin C Abba
- National Scientific and Technical Research Council, CONICET, Buenos Aires, Argentina.,Centro de Investigaciones Inmunológicas Básicas y Aplicadas, School of Medical Sciences, Universidad de La Plata, La Plata, Argentina
| | - François Doz
- Soins, Innovation, Recherche, en Oncologie de l'Enfant, de l'Adolescent et de l'Adulte Jeune (SIREDO) Oncology Center, Institut Curie, Paris, France
| | - Osvaldo Podhjacer
- National Scientific and Technical Research Council, CONICET, Buenos Aires, Argentina.,Laboratory of Molecular and Cellular Therapy, Instituto Leloir, Buenos Aires, Argentina
| | - Angel Montero Carcaboso
- Preclinical Therapeutics and Drug Delivery Research Program and Department of Pediatric Hematology and Oncology, Hospital Sant Joan de Deu, Barcelona, Spain
| | - Eric Letouzé
- Centre de Recherche des Cordeliers, Sorbonne Universités, Institut National de la Santé et de la Recherche Médicale, Paris, France.,Functional Genomics of Solid Tumor, Labex Immuno-Oncology, Équipe Labellisée Ligue Contre le Cancer, Université de Paris, Université Paris 13, Paris, France
| | - François Radvanyi
- Centre National de la Recherche Scientifique, Unité Mixte de Recherche 144, Institut Curie, Paris, France
| | - Guillermo L Chantada
- Precision Medicine, Hospital de Pediatría J.P. Garrahan, Buenos Aires, Argentina.,National Scientific and Technical Research Council, CONICET, Buenos Aires, Argentina
| | - Andrea S Llera
- National Scientific and Technical Research Council, CONICET, Buenos Aires, Argentina.,Laboratory of Molecular and Cellular Therapy, Instituto Leloir, Buenos Aires, Argentina
| | - Paula Schaiquevich
- Precision Medicine, Hospital de Pediatría J.P. Garrahan, Buenos Aires, Argentina.,National Scientific and Technical Research Council, CONICET, Buenos Aires, Argentina
| |
Collapse
|
6
|
Carnovale NR, Oviedo MF, Ganiewich D, Oppenheimer F, Leiros GJ, Olivares CN, Bilotas MA, Meresman GF. Development of decidualized and 3D human endometrial models for the study of human implantation and endocrine pathologies. Placenta 2019. [DOI: 10.1016/j.placenta.2019.06.071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|